Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) will present 18 abstracts featuring new and encore data from its neuropsychiatry portfolio at the APA and ASCP 2026 meetings.
Highlights include Phase 3 data for CAPLYTA, seltorexant, SPRAVATO, and guidance on long-acting injectables in schizophrenia, MDD, TRD, and insomnia symptoms.
Johnson & Johnson (NYSE: JNJ) launched Generation Fine on May 7, 2026, a global campaign to encourage patients with major depressive disorder (MDD) to seek remission rather than accept being "fine."
Campaign is based on a global survey: nearly 4 in 5 patients doubt antidepressants will achieve remission; about 2 in 3 report ongoing symptoms. Generation Fine partners with Mental Health America, features patient stories and advocates, and provides resources to support conversations with healthcare providers.
Johnson & Johnson (NYSE: JNJ) reported Phase 2b DUET-UC and DUET-CD results for JNJ-4804, an investigational co-antibody targeting IL-23 and TNF-α. At Week 48 the JNJ-4804 high-dose group showed higher clinical remission and endoscopic response rates versus golimumab and numerically higher rates versus guselkumab in UC and CD.
JNJ will advance JNJ-4804 into Phase 3 DUET ENCORE-CD and DUET ENCORE-UC trials; safety was described as generally consistent with known monotherapy profiles.
Johnson & Johnson (NYSE: JNJ) announced Phase 3 FUZION results showing TREMFYA (guselkumab) met the primary endpoint of combined fistula remission in adults with active perianal fistulizing Crohn's disease at Week 24.
Combined remission rates: 28.3% (100 mg q8w) and 27.0% (200 mg q4w) versus 10.3% placebo; both differences were statistically significant (p=0.007; p=0.013). Adverse events through 24 weeks were consistent with the known safety profile. The company is also initiating the CHARGE head-to-head study vs risankizumab for Crohn's disease.
Johnson & Johnson (NYSE:JNJ) reported results from a 30-patient prospective multicenter study of the investigational OTTAVA™ Robotic Surgical System in Roux-en-Y gastric bypass. The study met primary safety and performance endpoints through 30 days, with all procedures completed robotically and no conversions. Average 30-day weight loss was 30 pounds. Data and preclinical testing supported a De Novo submission to the U.S. FDA for multiple upper-abdomen general surgery indications. OTTAVA™ integrates four table-mounted robotic arms to fit space-constrained ORs and was used across six hospitals.
Johnson & Johnson (NYSE: JNJ) announced a network meta-analysis showing CAPLYTA (lumateperone) ranked highest among FDA‑approved adjunctive atypical antipsychotics across four efficacy measures for adults with adjunctive major depressive disorder (aMDD).
Key metrics: MADRS change MD -4.71; MADRS response OR 2.33; MADRS remission OR 2.22; CGI‑S change MD -0.60. Weight outcomes showed no significant gain versus placebo plus ADT.
Johnson & Johnson (NYSE: JNJ) appointed Ryan Koors as Vice President, Investor Relations, effective May 7, 2026. He will report to Executive Vice President and CFO Joseph J. Wolk and succeeds Darren Snellgrove, who is leaving to become CFO of Halozyme. Mr. Koors has 20+ years at Johnson & Johnson and previously served as CFO for Innovative Medicine Global R&D.
Johnson & Johnson (NYSE: JNJ) will present at Bernstein’s 42nd Annual Strategic Decisions Conference on Wednesday, May 27, 2026. Management will participate in a Fireside Chat at 11:00 a.m. ET.
A live audio webcast will be available at the company Investor Relations website and an archived replay will be posted; the audio replay is expected approximately 48 hours after the webcast.
Johnson & Johnson (NYSE: JNJ) announced the FDA granted Priority Review to the supplemental BLA for IMAAVY (nipocalimab-aahu) for warm autoimmune hemolytic anemia (wAIHA), shortening the U.S. review timeline to approximately six months.
The Priority Review is supported by the Phase 2/3 ENERGY study, in which IMAAVY achieved a durable hemoglobin response and improved fatigue versus placebo; full ENERGY results will be presented at an upcoming medical conference. IMAAVY is not yet approved for wAIHA.
Johnson & Johnson (NYSE: JNJ) reported long-term results for IMAAVY (nipocalimab-aahu) in antibody-positive adults with generalized myasthenia gravis, extending follow-up to 120 weeks. Key findings include sustained symptom improvements, mean MG-ADL reduction of 6.47 points, QMG reduction of 5.97, and durable IgG lowering.
Half of patients reached minimal symptom expression and 32% sustained it for at least 8 weeks; corticosteroid use fell with 57% at low doses. EPIC, a head-to-head study versus efgartigimod, is now enrolling.